{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T16:05:41Z","timestamp":1787069141960,"version":"build-2736575974"},"reference-count":30,"publisher":"American Academy of Pediatrics (AAP)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2006,5,1]]},"abstract":"<jats:p>BACKGROUND. Experts recommend that children with suspected pneumococcal meningitis should empirically receive combination therapy with vancomycin plus either ceftriaxone or cefotaxime. The relationship between timing of the first dose of vancomycin relative to other antibiotics and outcome in these children, however, has not been addressed.<\/jats:p>\n                  <jats:p>METHODS. Medical records of children with pneumococcal meningitis at a single institution from 1991\u20132001 were retrospectively reviewed. Vancomycin start time was defined as the number of hours from initiation of cefotaxime or ceftriaxone therapy until the administration of vancomycin therapy. Outcome variables were death, sensorineural hearing loss, and other neurologic deficits at discharge. Associations between independent variables and outcome variables were assessed in univariate and multiple logistic regression analyses.<\/jats:p>\n                  <jats:p>RESULTS. Of 114 subjects, 109 received empiric vancomycin therapy in combination with cefotaxime or ceftriaxone. Ten subjects (9%) died, whereas 37 (55%) of 67 survivors who underwent audiometry had documented hearing loss, and 14 (13%) of 104 survivors were discharged with other neurologic deficits. Subjects with hearing loss had a significantly shorter median vancomycin start time than did those with normal hearing (&amp;lt;1 vs 4 hours). Vancomycin start time was not significantly associated with death or other neurologic deficits in univariate or multivariate analyses. Multiple logistic regression revealed that hearing loss was independently associated with vancomycin start time &amp;lt;2 hours, blood leukocyte count &amp;lt;15000\/\u03bcL, and cerebrospinal fluid glucose concentration &amp;lt;30 mg\/dL.<\/jats:p>\n                  <jats:p>CONCLUSIONS. Early empiric vancomycin therapy was not clinically beneficial in children with pneumococcal meningitis but was associated with a substantially increased risk of hearing loss. It may be prudent to consider delaying the first dose of vancomycin therapy until \u22652 hours after the first dose of parenteral cephalosporin in children beginning therapy for suspected or confirmed pneumococcal meningitis.<\/jats:p>","DOI":"10.1542\/peds.2005-2282","type":"journal-article","created":{"date-parts":[[2006,5,1]],"date-time":"2006-05-01T13:22:05Z","timestamp":1146489725000},"page":"1688-1694","source":"Crossref","is-referenced-by-count":34,"title":["Early Vancomycin Therapy and Adverse Outcomes in Children With Pneumococcal Meningitis"],"prefix":"10.1542","volume":"117","author":[{"given":"Steven C.","family":"Buckingham","sequence":"first","affiliation":[{"name":"Department of Pediatrics, University of Tennessee Health Science Center and Children's Foundation Research Center at Le Bonheur Children's Medical Center, Memphis, Tennessee"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan A.","family":"McCullers","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, St. Jude Children's Research Hospital, Memphis, Tennessee"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Luja\u0301n-Zilbermann","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, University of South Florida, Tampa, Florida"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine M.","family":"Knapp","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, St. Jude Children's Research Hospital, Memphis, Tennessee"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen L.","family":"Orman","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Kosair Children's Hospital, Louisville, Kentucky"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B. Keith","family":"English","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, University of Tennessee Health Science Center and Children's Foundation Research Center at Le Bonheur Children's Medical Center, Memphis, Tennessee"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"417","published-online":{"date-parts":[[2006,5,1]]},"reference":[{"key":"2021120823251848900_R1","doi-asserted-by":"crossref","unstructured":"Dodge PR, Davis H, Feigin RD, et al. Prospective evaluation of hearing impairment as a sequela of acute bacterial meningitis. N Engl J Med.\u20081984;311:869\u2013874","DOI":"10.1056\/NEJM198410043111401"},{"key":"2021120823251848900_R2","doi-asserted-by":"crossref","unstructured":"Arditi M, Mason EO, Bradley JS, et al. Three-year multicenter surveillance of pneumococcal meningitis in children: clinical characteristics, and outcome related to penicillin susceptibility and dexamethasone use. Pediatrics.\u20081998;102:1087\u20131097","DOI":"10.1542\/peds.102.5.1087"},{"key":"2021120823251848900_R3","doi-asserted-by":"crossref","unstructured":"Kornelisse RF, Westerbeek CM, Spoor AB. Pneumococcal meningitis in children: prognostic indicators and outcome. Clin Infect Dis.\u20081995;21:1390\u20131397","DOI":"10.1093\/clinids\/21.6.1390"},{"key":"2021120823251848900_R4","doi-asserted-by":"crossref","unstructured":"McIntyre PB, Macintyre CR, Gilmour R, Wang H. A population based study of the impact of corticosteroid therapy and delayed diagnosis on the outcome of childhood pneumococcal meningitis. Arch Dis Child.\u20082005;90:391\u2013396","DOI":"10.1136\/adc.2003.037523"},{"key":"2021120823251848900_R5","doi-asserted-by":"crossref","unstructured":"Yogev R, Guzman-Cottrill J. Bacterial meningitis in children: critical review of current concepts. Drugs.\u20082005;65:1097\u20131112","DOI":"10.2165\/00003495-200565080-00005"},{"key":"2021120823251848900_R6","doi-asserted-by":"crossref","unstructured":"Whitney CG, Farley MM, Hadler J, et al. Increasing prevalence of multidrug-resistant Streptococcus pneumoniae in the United States. N Engl J Med.\u20082000;343:1917\u20131924","DOI":"10.1056\/NEJM200012283432603"},{"key":"2021120823251848900_R7","doi-asserted-by":"crossref","unstructured":"Bradley JS, Connor JD. Ceftriaxone failure in meningitis caused by Streptococcus pneumoniae with reduced susceptibility to beta-lactam antibiotics. Pediatr Infect Dis J.\u20081991;10:871\u2013873","DOI":"10.1097\/00006454-199111000-00018"},{"key":"2021120823251848900_R8","unstructured":"Sloas MM, Barrett FF, Chesney PJ, et al. Cephalosporin treatment failure in penicillin- and cephalosporin-resistant Streptococcus pneumoniae meningitis. Pediatr Infect Dis J.\u20081992;11:662\u2013666"},{"key":"2021120823251848900_R9","doi-asserted-by":"crossref","unstructured":"Catala\u0301n MJ, Ferna\u0301ndez JM, Vazquez A, Varela de Seijas E, Sua\u0301rez A, Bernaldo deq Uiro\u0301s JC. Failure of cefotaxime in the treatment of meningitis due to relatively resistant Streptococcus pneumoniae.Clin Infect Dis.\u20081994;18:766\u2013769","DOI":"10.1093\/clinids\/18.5.766"},{"key":"2021120823251848900_R10","doi-asserted-by":"crossref","unstructured":"John CC. Treatment failure with use of a third-generation cephalosporin for penicillin-resistant pneumococcal meningitis: case report and review. Clin Infect Dis.\u20081994;18:188\u2013193","DOI":"10.1093\/clinids\/18.2.188"},{"key":"2021120823251848900_R11","doi-asserted-by":"crossref","unstructured":"American Academy of Pediatrics, Committee on Infectious Diseases. Therapy for children with invasive pneumococcal infections. Pediatrics.\u20081997;99:289\u2013299","DOI":"10.1542\/peds.99.2.289"},{"key":"2021120823251848900_R12","doi-asserted-by":"crossref","unstructured":"Lebel MH, McCracken GH. Delayed cerebrospinal fluid sterilization and adverse outcome of bacterial meningitis in infants and children. Pediatrics.\u20081989;83:161\u2013167","DOI":"10.1542\/peds.83.2.161"},{"key":"2021120823251848900_R13","doi-asserted-by":"crossref","unstructured":"Buckingham SC, McCullers JA, Lujan-Zilbermann J, Knapp KM, Orman KL, English BK. Pneumococcal meningitis in children: relationship of antibiotic resistance to clinical characteristics and outcomes. Pediatr Infect Dis J.\u20082001;20:837\u2013843","DOI":"10.1097\/00006454-200109000-00003"},{"key":"2021120823251848900_R14","unstructured":"American Academy of Pediatrics. Pneumococcal infections. In: Pickering LK, ed. Red Book: 2003 Report of the Committee on Infectious Diseases. 26th ed. Elk Grove Village, IL: American Academy of Pediatrics; 2003:490\u2013500"},{"key":"2021120823251848900_R15","unstructured":"Clinical and Laboratory Standards Institute\/NCCLS. Performance Standards for Antimicrobial Susceptibility Testing: Fifteenth Informational Supplement. Wayne, PA: Clinical and Laboratory Standards Institute; 2005 CLSI\/NCCLS document M100-S15"},{"key":"2021120823251848900_R16","unstructured":"Sackett DL, Straus SE, Richardson WS, Rosenberg W, Haynes RB. Evidence-Based Medicine: How to Practice and Teach EBM. Edinburgh, United Kingdom: Churchill Livingstone; 2000"},{"key":"2021120823251848900_R17","doi-asserted-by":"crossref","unstructured":"McMaster P, McIntyre P, Gilmour R, Gilbert L, Kakakios A, Mellis C. The emergence of resistant pneumococcal meningitis\u2013implications for empiric therapy. Arch Dis Child.\u20082002;87:207\u2013210","DOI":"10.1136\/adc.87.3.207"},{"key":"2021120823251848900_R18","doi-asserted-by":"crossref","unstructured":"Kellner JD, Scheifele DW, Halperin SA, et al. Outcome of penicillin-nonsusceptible Streptococcus pneumoniae meningitis: a nested case-control study. Pediatr Infect Dis J.\u20082002;21:903\u2013910","DOI":"10.1097\/00006454-200210000-00004"},{"key":"2021120823251848900_R19","doi-asserted-by":"crossref","unstructured":"Stanek RJ, Mufson MA. A 20-year epidemiological study of pneumococcal meningitis. Clin Infect Dis.\u20081999;28:1265\u20131272","DOI":"10.1086\/514777"},{"key":"2021120823251848900_R20","doi-asserted-by":"crossref","unstructured":"Desbiolles N, Piroth L, Lequeu C, Neuwirth C, Portier H, Chavanet P. Fractional maximal effect method for in vitro synergy between amoxicillin and ceftriaxone and between vancomycin and ceftriaxone against Enterococcus faecalis and penicillin-resistant Streptococcus pneumoniae.Antimicrob Agents Chemother.\u20082001;45:3328\u20133333","DOI":"10.1128\/AAC.45.12.3328-3333.2001"},{"key":"2021120823251848900_R21","doi-asserted-by":"crossref","unstructured":"Bajaksouzian S, Visalli MA, Jacobs MR, Appelbaum PC. Antipneumococcal activities of cefpirome and cefotaxime, alone and in combination with vancomycin and teicoplanin, determined by checkerboard and time-kill methods. Antimicrob Agents Chemother.\u20081996;40:1973\u20131976","DOI":"10.1128\/AAC.40.9.1973"},{"key":"2021120823251848900_R22","doi-asserted-by":"crossref","unstructured":"Gerber CM, Cottagnoud M, Neftel KA, Tauber MG, Cottagnoud P. Meropenem alone and in combination with vancomycin in experimental meningitis caused by a penicillin-resistant pneumococcal strain. Eur J Clin Microbiol Infect Dis.\u20081999;18:866\u2013870","DOI":"10.1007\/s100960050421"},{"key":"2021120823251848900_R23","doi-asserted-by":"crossref","unstructured":"Nau R, Eiffert H. Modulation of release of proinflammatory bacterial compounds by antibacterials: potential impact on course of inflammation and outcome in sepsis and meningitis. Clin Microbiol Rev.\u20082002;15:95\u2013110","DOI":"10.1128\/CMR.15.1.95-110.2002"},{"key":"2021120823251848900_R24","doi-asserted-by":"crossref","unstructured":"de Gans J, van de Beek D. European Dexamethasone in Adulthood Bacterial Meningitis Study Investigators. Dexamethasone in adults with bacterial meningitis. N Engl J Med.\u20082002;347:1549\u20131556","DOI":"10.1056\/NEJMoa021334"},{"key":"2021120823251848900_R25","doi-asserted-by":"crossref","unstructured":"van de Beek D, de Gans J, McIntyre P, Prasad K. Corticosteroids for acute bacterial meningitis. Cochrane Database Syst Rev.\u20082003;(3):CD004305","DOI":"10.1002\/14651858.CD004405"},{"key":"2021120823251848900_R26","doi-asserted-by":"crossref","unstructured":"McIntyre PB, Berkey CS, King SM, et al. Dexamethasone as adjunctive therapy in bacterial meningitis: a meta-analysis of randomized clinical trials since 1988. JAMA.\u20081997;278:925\u2013931","DOI":"10.1001\/jama.278.11.925"},{"key":"2021120823251848900_R27","doi-asserted-by":"crossref","unstructured":"Nau R, Wellmer A, Soto A. Rifampin reduces early mortality in experimental Streptococcus pneumoniae meningitis. J Infect Dis.\u20081999;179:1557\u20131560","DOI":"10.1086\/314760"},{"key":"2021120823251848900_R28","doi-asserted-by":"crossref","unstructured":"Spreer A, Kerstan H, Bottcher T, et al. Reduced release of pneumolysin by Streptococcus pneumoniae in vitro and in vivo after treatment with nonbacteriolytic antibiotics in comparison to ceftriaxone. Antimicrob Agents Chemother.\u20082003;47:2649\u20132654","DOI":"10.1128\/AAC.47.8.2649-2654.2003"},{"key":"2021120823251848900_R29","doi-asserted-by":"crossref","unstructured":"Gerber J, Pohl K, Sander V, Bunkowski S, Nau R. Rifampin followed by ceftriaxone for experimental meningitis decreases lipoteichoic acid concentrations in cerebrospinal fluid and reduces neuronal damage in comparison to ceftriaxone alone. Antimicrob Agents Chemother.\u20082003;47:1313\u20131317","DOI":"10.1128\/AAC.47.4.1313-1317.2003"},{"key":"2021120823251848900_R30","doi-asserted-by":"crossref","unstructured":"Kaplan SL, Mason EO Jr, Wald ER, et al. Decrease of invasive pneumococcal infections in children among 8 children's hospitals in the United States after the introduction of the 7-valent pneumococcal conjugate vaccine. Pediatrics.\u20082004;113:443\u2013449","DOI":"10.1542\/peds.113.3.443"}],"container-title":["Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/117\/5\/1688\/1070506\/zpe00506001688.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/117\/5\/1688\/1070506\/zpe00506001688.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,7]],"date-time":"2023-05-07T04:36:48Z","timestamp":1683434208000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.aap.org\/pediatrics\/article\/117\/5\/1688\/70026\/Early-Vancomycin-Therapy-and-Adverse-Outcomes-in"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,5,1]]},"references-count":30,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2006,5,1]]},"published-print":{"date-parts":[[2006,5,1]]}},"URL":"https:\/\/doi.org\/10.1542\/peds.2005-2282","relation":{},"ISSN":["0031-4005","1098-4275"],"issn-type":[{"value":"0031-4005","type":"print"},{"value":"1098-4275","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,5,1]]}}}